Tech Company Financing Transactions
GrayBug Vision Funding Round
GrayBug Vision secured a $44.5 million Series B funding round on 5/2/2016. Investors included Deerfield Capital, Clarus and OrbiMed.
Transaction Overview
Company Name
Announced On
5/2/2016
Transaction Type
Venture Equity
Amount
$44,500,000
Round
Series B
Investors
Proceeds Purpose
The proceeds will be used to further the development of GB-102, Graybug Vision's lead drug for wet AMD, through Phase 2 clinical trials and to initiate a clinical program for the company's proprietary glaucoma compound. GB-102, a dual acting inhibitor of VEGF and PDGF receptors, may be administered twice per year in wet AMD patients.
Company Information
Company Status
Publicly-held
Industry
Medical Devices & Instruments
Mailing Address
275 Shoreline Dr. 450
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
Graybug Vision (Nasdaq: GRAY) is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frédéric Guerard
Chief Medical Officer
Charles Semba
Chief Operating Officer
Daniel Salain
VP - Operations
Valerie Smith
VP - Product Management
Rajendra Mohabir
VP - R & D
Ming Yang
VP - Regulatory Affairs
Karl Trass
Browse more venture capital transactions:
Prev: 4/30/2016: World View venture capital transaction
Next: 5/2/2016: Metamason venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs